Capricor Therapeutics (CAPR) Misses Q1 EPS by 2c

Capricor Therapeutics (NASDAQ: CAPR) reported Q1 EPS of ($0.14), $0.02 worse than the analyst estimate of ($0.12).

For earnings history and earnings-related data on Capricor Therapeutics (CAPR) click here.

You May Also Be Interested In

• These Biotech Breakouts and Squeeze Setups Could Be Just Getting Started
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance